WHITE-C_Kexing Biopharmaceutical Official Website



    尊龙凯时 - 人生就是搏!中国官方网站

    3358288340
    CN
    CN EN
    Human Granulocyte Colony-stimulating Factor Injection
    Since its introduction into the market in 1999, WHITE-C has been clinically applied for more than 20 years, with a wide range of evidence-based applications, topping the list of domestic similar products in terms of export volume. As strict in-house control quality standards are followed, WHITE-C is not only in line with Chinese Pharmacopoeia, but also European Pharmacopoeia.
    Drug description

    【Indications】

    ①Neutropenia due to cancer chemotherapy and other reasons;

    ②Neutropenia due to chemotherapy for acute leukemia.


    【R&D and Commercial Production of WHITE-C】

    In 1990, an efficiently and stably expressed G-CSF engineered cell line was constructed;


    In 1992, preclinical pilot-scale production processes and preclinical animal trials were successfully completed;


    In 1994, clinical trial application was submitted;


    In 1998, the phase I/II clinical trial approved by the Bureau of Drug Policy & Administration of Ministry of Health was completed;


    In 1999, the new drug certificate issued by the Ministry of Health was obtained;


    In 2000, trial production was conducted and various tests by the National Institutes for Food and Drug Control were passed;


    In 2001, the approval for formal production was obtained;


    In 2009, supplementary approval was obtained for the prefilled syringe;


    In 2017, pegylated human granulocyte colony-stimulating factor for injection was approved for research and development.

    Drug description
    友情链接: